PE20081630A1 - Quinazolinas para la inhibicion de pdk1 - Google Patents

Quinazolinas para la inhibicion de pdk1

Info

Publication number
PE20081630A1
PE20081630A1 PE2008000067A PE2008000067A PE20081630A1 PE 20081630 A1 PE20081630 A1 PE 20081630A1 PE 2008000067 A PE2008000067 A PE 2008000067A PE 2008000067 A PE2008000067 A PE 2008000067A PE 20081630 A1 PE20081630 A1 PE 20081630A1
Authority
PE
Peru
Prior art keywords
alkyl
bencensulfonamide
halo
pdk1
compounds
Prior art date
Application number
PE2008000067A
Other languages
English (en)
Inventor
Savithri Ramurthy
Xiaodong Lin
Sharada Subramanian
Alice C Rico
Xiaojing M Wang
Rama Jain
Jeremy M Murray
Steven E Basham
Robert L Warne
Wei Shu
Yashen Zhou
Jeffrey Dove
Mina Aikawa
Payman Amiri
Original Assignee
Novartis Vaccines & Diagnostic
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Vaccines & Diagnostic filed Critical Novartis Vaccines & Diagnostic
Publication of PE20081630A1 publication Critical patent/PE20081630A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/78—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
    • C07D239/84—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/08—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing alicyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D411/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms
    • C07D411/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D411/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Abstract

SE REFIERE A COMPUESTOS DERIVADOS DE QUINAZOLINA DE FORMULA (I) DONDE Ar ES ARILO(C6-C14) O HETEROARILO OPCIONALMENTE SUSTITUIDOS CON AMINO, CARBOXILO, CN, HALO, ENTRE OTROS; R1 ES H, ALQUILO(C1-C3), HALO, CN, CF3, ENTRE OTROS; R2 ES H, ALQUILO(C1-C10), ALCOXILO(C1-C10), CN, ENTRE OTROS; R3 ES H, HALO, CN, CARBOXILO, ALQUILO(C1-C10), ENTRE OTROS; L ES UN ENLACE COVALENTE, CARBONILO, -O-, -S-, -SO-, ENTRE OTROS; A1 ES ALQUILO(C1-C10), ALQUENILO(C2-C6), ALQUINILO(C2-C6), ALCOXILO(C1-C10), ENTRE OTROS. SON COMPUESTOS PREFERIDOS: 4-(6-BROMO-8-METOXIQUINAZOLIN-2-ILAMINO)BENCENSULFONAMIDA, 4-(6-ETINIL-8-METOXIQUINAZOLIN-2-ILAMINO)BENCENSULFONAMIDA, 4-(6-CIANO-8-METOXIQUINAZOLIN-2-ILAMINO)BENCENSULFONAMIDA, ENTRE OTROS. SE REFIERE TAMBIEN A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON INHIBIDORES DE LA QUINASA DEPENDIENTE DE 3-FOSFOINOSITIDO 1 (PDK1) SIENDO UTILES EN EL TRATAMIENTO DE CANCER DE PULMON, CANCER DE MAMA, LEUCEMIA, ARTRITIS, PSORIASIS
PE2008000067A 2006-12-22 2008-01-02 Quinazolinas para la inhibicion de pdk1 PE20081630A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US87697206P 2006-12-22 2006-12-22
US99917007P 2007-10-15 2007-10-15

Publications (1)

Publication Number Publication Date
PE20081630A1 true PE20081630A1 (es) 2008-12-14

Family

ID=39563215

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2008000067A PE20081630A1 (es) 2006-12-22 2008-01-02 Quinazolinas para la inhibicion de pdk1

Country Status (25)

Country Link
US (1) US20100216767A1 (es)
EP (1) EP2125755A2 (es)
JP (1) JP2010514693A (es)
KR (1) KR20090092287A (es)
CN (1) CN101652352A (es)
AR (1) AR065231A1 (es)
AU (1) AU2007336893A1 (es)
BR (1) BRPI0720563A2 (es)
CA (1) CA2673003A1 (es)
CL (1) CL2007003774A1 (es)
CO (1) CO6361927A2 (es)
CR (1) CR10833A (es)
EA (1) EA200900819A1 (es)
EC (1) ECSP099445A (es)
IL (1) IL198774A0 (es)
MA (1) MA31001B1 (es)
MX (1) MX2009006627A (es)
NO (1) NO20092725L (es)
PE (1) PE20081630A1 (es)
SM (1) SMP200900055B (es)
SV (1) SV2009003307A (es)
TN (1) TN2009000255A1 (es)
TW (1) TW200829558A (es)
WO (1) WO2008079988A2 (es)
ZA (1) ZA200903233B (es)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UY31137A1 (es) * 2007-06-14 2009-01-05 Smithkline Beecham Corp Derivados de quinazolina como inhibidores de la pi3 quinasa
US20100311965A1 (en) * 2007-12-28 2010-12-09 Carna Biosciences Inc. 2-aminoquinazoline derivative
WO2009131173A1 (ja) * 2008-04-23 2009-10-29 協和発酵キリン株式会社 2-アミノキナゾリン誘導体
US20100121052A1 (en) * 2008-06-20 2010-05-13 Rama Jain Novel compounds for treating proliferative diseases
WO2010011871A2 (en) * 2008-07-23 2010-01-28 The Regents Of The University Of California Methods and compositions for providing salicylic acid-independent pathogen resistance in plants
ES2432414T3 (es) * 2008-08-12 2013-12-03 Glaxosmithkline Llc Compuestos químicos
JP2012514020A (ja) * 2008-12-29 2012-06-21 フォーヴィア・ファーマシューティカルズ 置換キナゾリン化合物
CN102317288A (zh) 2009-02-13 2012-01-11 佛维雅制药公司 作为激酶抑制剂的[1,2,4]三唑并[1,5-a]吡啶
GB201007286D0 (en) 2010-04-30 2010-06-16 Astex Therapeutics Ltd New compounds
AR081960A1 (es) 2010-06-22 2012-10-31 Fovea Pharmaceuticals Sa Compuestos heterociclicos, su preparacion y su aplicacion terapeutica
CN101921238B (zh) * 2010-08-04 2012-04-04 苏州大学附属第一医院 取代苯并氮杂环类衍生物的制备及其药理用途
JP5916730B2 (ja) * 2010-09-06 2016-05-11 グアンジョウ インスティテュート オブ バイオメディスン アンド ヘルス，チャイニーズ アカデミー オブ サイエンスィズ アミド化合物
EP2632263A1 (en) * 2010-10-29 2013-09-04 Merck Sharp & Dohme Corp. Novel thiazole-carboxamide derivatives as pdk1 inhibitors
DE102010049877A1 (de) 2010-11-01 2012-05-03 Merck Patent Gmbh 7-((1,2,3)Triazol-4-yl)-pyrrolo(2,3) pyrazinderivate
EP2642856B1 (en) 2010-11-24 2017-07-19 The Ohio State University Research Foundation Integrin-linked kinase inhibitors
GB201020179D0 (en) 2010-11-29 2011-01-12 Astex Therapeutics Ltd New compounds
DE102011008352A1 (de) 2011-01-12 2012-07-12 Merck Patent Gmbh 5-([1,2,3]Triazol-4-yl)-7H-pyrrolo-[2,3-d]pyrimidinderivate
DE102011009961A1 (de) 2011-02-01 2012-08-02 Merck Patent Gmbh 7-Azaindolderivate
AU2012317457B2 (en) * 2011-09-29 2016-09-29 Ono Pharmaceutical Co., Ltd. Phenyl derivative
GB201118675D0 (en) 2011-10-28 2011-12-14 Astex Therapeutics Ltd New compounds
GB201118654D0 (en) 2011-10-28 2011-12-07 Astex Therapeutics Ltd New compounds
GB201118656D0 (en) 2011-10-28 2011-12-07 Astex Therapeutics Ltd New compounds
GB201118652D0 (en) 2011-10-28 2011-12-07 Astex Therapeutics Ltd New compounds
GB201209609D0 (en) 2012-05-30 2012-07-11 Astex Therapeutics Ltd New compounds
GB201209613D0 (en) 2012-05-30 2012-07-11 Astex Therapeutics Ltd New compounds
DK2872491T3 (da) * 2012-07-11 2021-08-09 Blueprint Medicines Corp Inhibitorer af fibroblastvækstfaktorreceptoren
GB201216018D0 (en) * 2012-09-07 2012-10-24 Cancer Rec Tech Ltd Pharmacologically active compounds
GB201216017D0 (en) 2012-09-07 2012-10-24 Cancer Rec Tech Ltd Inhibitor compounds
DE102012019369A1 (de) 2012-10-02 2014-04-03 Merck Patent Gmbh 7-Azaindolderivat
TR201808812T4 (tr) 2013-03-26 2018-07-23 Ono Pharmaceutical Co Fenil derivesi.
GB201307577D0 (en) 2013-04-26 2013-06-12 Astex Therapeutics Ltd New compounds
PT3027600T (pt) 2013-07-31 2022-06-23 Novartis Ag Derivados de piridazina 1,4-dissubstituídos e a sua utilização para tratamento de condições relacionadas com deficiência em smn
EP3670496A3 (en) * 2013-10-17 2020-09-30 Shionogi&Co., Ltd. Acc2 inhibitors
RS60136B1 (sr) 2013-10-18 2020-05-29 Celgene Quanticel Research Inc Inhibitori bromodomena
EP3060560A1 (en) 2013-10-25 2016-08-31 Blueprint Medicines Corporation Inhibitors of the fibroblast growth factor receptor
US9695165B2 (en) 2014-01-15 2017-07-04 Blueprint Medicines Corporation Inhibitors of the fibroblast growth factor receptor
GB201403536D0 (en) 2014-02-28 2014-04-16 Cancer Rec Tech Ltd Inhibitor compounds
JO3512B1 (ar) 2014-03-26 2020-07-05 Astex Therapeutics Ltd مشتقات كينوكسالين مفيدة كمعدلات لإنزيم fgfr كيناز
LT3122358T (lt) 2014-03-26 2021-04-12 Astex Therapeutics Ltd. Egfr ir cmet inhibitorių deriniai, skirti vėžio gydymui
HUE053653T2 (hu) 2014-03-26 2021-07-28 Astex Therapeutics Ltd FGFR inhibitor és IGF1R inhibitor kombinációi
JOP20200201A1 (ar) 2015-02-10 2017-06-16 Astex Therapeutics Ltd تركيبات صيدلانية تشتمل على n-(3.5- ثنائي ميثوكسي فينيل)-n'-(1-ميثيل إيثيل)-n-[3-(ميثيل-1h-بيرازول-4-يل) كينوكسالين-6-يل]إيثان-1.2-ثنائي الأمين
CA2979792C (en) * 2015-02-24 2023-04-04 Gene Techno Science Co., Ltd. Method for diagnosing, preventing and treating cancer brain metastasis, and drug delivery system for enabling passage through blood-brain barrier
US10478494B2 (en) 2015-04-03 2019-11-19 Astex Therapeutics Ltd FGFR/PD-1 combination therapy for the treatment of cancer
CA2992945A1 (en) 2015-07-17 2017-01-26 Memorial Sloan-Kettering Cancer Center Combination therapy using pdk1 and pi3k inhibitors
HRP20220012T1 (hr) 2015-09-23 2022-04-01 Janssen Pharmaceutica Nv Bi-heteroaril supstituirani 1,4-benzodiazepini i njihova upotreba za liječenje raka
CN108026095B (zh) 2015-09-23 2021-07-27 詹森药业有限公司 新化合物
EP3868751B1 (en) 2015-10-02 2023-10-25 Sentinel Oncology Limited 2-aminoquinazoline derivatives as p70s6 kinase inhibitors
GB201705263D0 (en) * 2017-03-31 2017-05-17 Probiodrug Ag Novel inhibitors
GB201709840D0 (en) 2017-06-20 2017-08-02 Inst Of Cancer Research: Royal Cancer Hospital Methods and medical uses
RU2764243C2 (ru) 2017-09-22 2022-01-14 ДЖУБИЛАНТ ЭПИПЭД ЭлЭлСи Гетероциклические соединения в качестве ингибиторов PAD
HUE061607T2 (hu) 2017-10-18 2023-07-28 Jubilant Epipad LLC Imidazopiridin vegyületek mint PAD inhibitorok
CA3080677A1 (en) 2017-11-06 2019-05-09 Jubilant Prodel LLC Pyrimidine derivatives as inhibitors of pd1/pd-l1 activation
EP3704120B1 (en) 2017-11-24 2024-03-06 Jubilant Episcribe LLC Heterocyclic compounds as prmt5 inhibitors
AU2019234185A1 (en) 2018-03-13 2020-10-01 Jubilant Prodel LLC. Bicyclic compounds as inhibitors of PD1/PD-L1 interaction/activation
US20230399327A1 (en) * 2020-10-28 2023-12-14 Adlai Nortye Biopharma Co., Ltd. High activity hpk1 kinase inhibitor
CN113999206B (zh) * 2021-12-31 2022-04-12 北京鑫开元医药科技有限公司 异喹啉-1,3-二胺类似物、制备方法、药物组合物及其应用
CN114533733A (zh) * 2021-12-31 2022-05-27 北京鑫开元医药科技有限公司 一种异喹啉-1,3-二胺类似物药物制剂及其制备方法
WO2023138412A1 (en) * 2022-01-20 2023-07-27 Insilico Medicine Ip Limited Fused pyrimidin-2-amine compounds as cdk20 inhibitors
WO2023218241A1 (en) * 2022-05-13 2023-11-16 Voronoi Inc. Heteroaryl derivative compounds, and pharmaceutical composition comprising thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006118256A1 (ja) * 2005-04-28 2006-11-09 Kyowa Hakko Kogyo Co., Ltd. 2-アミノキナゾリン誘導体
TW200808739A (en) * 2006-04-06 2008-02-16 Novartis Vaccines & Diagnostic Quinazolines for PDK1 inhibition
WO2008020203A1 (en) * 2006-08-17 2008-02-21 Astrazeneca Ab Pyridinylquinaz0linamine derivatives and their use as b-raf inhibitors
TW200829566A (en) * 2006-12-08 2008-07-16 Astrazeneca Ab Chemical compounds

Also Published As

Publication number Publication date
WO2008079988A2 (en) 2008-07-03
CR10833A (es) 2009-07-03
EA200900819A1 (ru) 2010-02-26
TN2009000255A1 (en) 2010-10-18
JP2010514693A (ja) 2010-05-06
SMAP200900055A (it) 2009-09-07
MX2009006627A (es) 2009-08-12
US20100216767A1 (en) 2010-08-26
SV2009003307A (es) 2010-05-21
CL2007003774A1 (es) 2008-04-18
TW200829558A (en) 2008-07-16
BRPI0720563A2 (pt) 2014-02-04
KR20090092287A (ko) 2009-08-31
AU2007336893A1 (en) 2008-07-03
AR065231A1 (es) 2009-05-27
WO2008079988A9 (en) 2011-05-12
WO2008079988A3 (en) 2008-10-16
CA2673003A1 (en) 2008-07-03
EP2125755A2 (en) 2009-12-02
MA31001B1 (fr) 2009-12-01
NO20092725L (no) 2009-09-22
SMP200900055B (it) 2010-05-07
CN101652352A (zh) 2010-02-17
ZA200903233B (en) 2010-04-28
IL198774A0 (en) 2010-02-17
CO6361927A2 (es) 2012-01-20
ECSP099445A (es) 2009-07-31

Similar Documents

Publication Publication Date Title
PE20081630A1 (es) Quinazolinas para la inhibicion de pdk1
PE20070427A1 (es) Compuestos derivados de benzimidazoles sustituidos como inhibidores de tirosina quinasas
PE20110424A1 (es) Isoindolonas que inhiben la cinasa mek
CO6351737A2 (es) Amidofenoxiindazoles utiles como inhibidores de c-met
PE20090601A1 (es) Derivados de piridin-il-oxi-piridinas como inhibidores de alk5
PH12014500947B1 (en) 1,2,5-oxadiazoles as inhibitors of indoleamine 2,3-dioxygenase
PE20140975A1 (es) Derivados de imidazopirazina como inhibidores de syk
SMAP201100019A (it) Composti organici.
PE20140609A1 (es) Diazacarbazoles y metodos de uso
JO2732B1 (en) Organic compounds
PE20141823A1 (es) Derivados de tetrahidro-quinazolinona
TW200914429A (en) Method for preparing 5-haloalkyl-4,5-dihydroisoxazole derivatives
PE20070855A1 (es) Derivados de 4-amino-pirrolotriazina sustituida como inhibidores de quinasas
NZ594385A (en) Aminopyrimidines useful as kinase inhibitors
PE20160654A1 (es) Compuestos de inhibidor de autotaxina
PE20081354A1 (es) Compuestos de azaindolilo como inhibidores de mek
PE20060215A1 (es) 4-fenilamino-quinazolin-6-il-amidas
PE20141203A1 (es) Benzilindazoles sustituidos para uso como inhibidores de la quinasa bub1 en el tratamiento de enfermedades hiperproliferativas
NZ608285A (en) Manufacturing process for pyrimidine derivatives
PE20061490A1 (es) Derivados de ciclohexanosulfonilo como inhibidores del transportador de glicina glyt1
PE20110062A1 (es) N-(3-(3,5-dimetoxifenetil)-1h-pirazol-5-il)-4-(3,4-dimetilpiperazin-1-il)benzamida y sales del mismo
MY149512A (en) Pyrazolylaminopyridine derivatives useful as kinase inhibitors
PE20091491A1 (es) Compuestos novedosos que son inhibidores de erk
PE20130150A1 (es) Inhibidores de las iap
PE20140192A1 (es) Derivados de bencimidazol como inhibidores de cinasa pi3

Legal Events

Date Code Title Description
FD Application declared void or lapsed